MX2020010030A - Metodos y composiciones que comprenden proteina d tensoactiva (sp-d). - Google Patents

Metodos y composiciones que comprenden proteina d tensoactiva (sp-d).

Info

Publication number
MX2020010030A
MX2020010030A MX2020010030A MX2020010030A MX2020010030A MX 2020010030 A MX2020010030 A MX 2020010030A MX 2020010030 A MX2020010030 A MX 2020010030A MX 2020010030 A MX2020010030 A MX 2020010030A MX 2020010030 A MX2020010030 A MX 2020010030A
Authority
MX
Mexico
Prior art keywords
surfactant protein
methods
compositions
recombinant human
active fragments
Prior art date
Application number
MX2020010030A
Other languages
English (en)
Inventor
Mark Cornell Manning
Shawn Grant
Jan Susan Rosenbaum
Derrick S Katayama
Giovanni M Pauletti
Ryan Holcomb
Original Assignee
Airway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Airway Therapeutics Inc filed Critical Airway Therapeutics Inc
Publication of MX2020010030A publication Critical patent/MX2020010030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Algunas modalidades proporcionadas en la presente se relacionan con métodos y composiciones farmacéuticas que comprenden proteína D tensoactiva humana recombinante o fragmentos activos de la misma. Algunas de esas modalidades incluyen soluciones o suspensiones y formas sólidas liofilizadas de proteína D tensoactiva humana recombinante o fragmentos activos de las mismas.
MX2020010030A 2018-03-29 2019-03-27 Metodos y composiciones que comprenden proteina d tensoactiva (sp-d). MX2020010030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650142P 2018-03-29 2018-03-29
PCT/US2019/024305 WO2019191247A1 (en) 2018-03-29 2019-03-27 Methods and compositions comprising surfactant protein d (sp-d)

Publications (1)

Publication Number Publication Date
MX2020010030A true MX2020010030A (es) 2021-01-15

Family

ID=68060728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010030A MX2020010030A (es) 2018-03-29 2019-03-27 Metodos y composiciones que comprenden proteina d tensoactiva (sp-d).

Country Status (12)

Country Link
US (1) US20210121536A1 (es)
EP (1) EP3774875A4 (es)
JP (1) JP2021519757A (es)
KR (1) KR20210007961A (es)
CN (1) CN112119088A (es)
AU (1) AU2019243707B2 (es)
BR (1) BR112020019861A2 (es)
CA (1) CA3095043A1 (es)
IL (1) IL277468B1 (es)
MX (1) MX2020010030A (es)
RU (1) RU2020131642A (es)
WO (1) WO2019191247A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145915A1 (ja) * 2022-01-31 2023-08-03 積水メディカル株式会社 肺サーファクタントプロテインの免疫測定方法及び免疫測定試薬
WO2023145916A1 (ja) * 2022-01-31 2023-08-03 積水メディカル株式会社 肺サーファクタントプロテインを含む液状組成物、及びそれを含む免疫測定キット、並びに肺サーファクタントプロテインの保存安定性向上方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838428B2 (en) * 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US8933032B2 (en) * 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
JP3573330B2 (ja) * 1999-07-22 2004-10-06 ヤマサ醤油株式会社 安定化された抗原含有水溶液
HUE045638T2 (hu) * 2011-01-05 2020-01-28 Prenatal Int Gmbh Hipotóniás vizes készítmény csökkentett klorid-tartalommal, foszfolipidekkel vagy anélkül
US20120220531A1 (en) * 2011-02-04 2012-08-30 Cincinnati Children's Hospital Medical Center Surfactant protein d for the treatment of disorders associated with lung injury
EP2946766B1 (en) * 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
MA44252A (fr) * 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation

Also Published As

Publication number Publication date
EP3774875A4 (en) 2022-01-12
BR112020019861A2 (pt) 2021-01-05
WO2019191247A1 (en) 2019-10-03
AU2019243707A1 (en) 2020-10-15
CN112119088A (zh) 2020-12-22
EP3774875A1 (en) 2021-02-17
JP2021519757A (ja) 2021-08-12
US20210121536A1 (en) 2021-04-29
AU2019243707B2 (en) 2023-12-07
KR20210007961A (ko) 2021-01-20
IL277468B1 (en) 2024-05-01
CA3095043A1 (en) 2019-10-03
IL277468A (en) 2020-11-30
RU2020131642A (ru) 2022-04-29

Similar Documents

Publication Publication Date Title
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
PH12018500594A1 (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
PH12020550051A1 (en) Glp-1 compositions and uses thereof
WO2018160754A3 (en) Inducible monovalent antigen binding protein
WO2016070166A3 (en) Messenger una molecules and uses thereof
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
WO2019035880A8 (en) EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF
MY190926A (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
MX2019013151A (es) Composiciones y metodos para expresar otoferlina.
EP3735458A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2022014533A (es) Metodo para seleccionar proteinas recombinantes ricas en m6p.
CL2020003355A1 (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
PH12017500450A1 (en) Flavivirus virus like particle
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
WO2018170150A3 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
MX2020010030A (es) Metodos y composiciones que comprenden proteina d tensoactiva (sp-d).
EA201791918A1 (ru) Модификация белков клеток-хозяев
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
WO2019014260A3 (en) BLOOD COMPONENT POTENTIATION OF ANTIBACTERIAL ACTIVITY OF THE LYTIC PROTEIN AND METHODS AND USES THEREOF
EP3994275A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
MY187334A (en) Xylanase
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.